


+ Evidence in focus

Effective management of biofilms and local infections using the new infection management (IM) pathway

+ Plus points

The IM pathway:



Background¹

CHALLENGES OF TREATING BIOFILMS AND LOCAL INFECTIONS

An international survey was conducted in February 2020

Of respondents:



(418 respondents; 82% completion rate; 72% wound care specialists, majority [77%] from New Zealand, Australia, USA, Europe)

Survey results suggest that non-specialists need support and guidance with managing biofilms and local infections and so the IM pathway tool was developed

The IM pathway¹

SIMPLIFYING WOUND INFECTION ASSESSMENT AND DIAGNOSIS


Simple, evidence-based, easy-to-use tool created by an international multidisciplinary expert panel to:

- ✓ Simplify differentiation and diagnosis of biofilms and local infections
- ✓ Guide early and appropriate management and selection of antimicrobials, supporting antimicrobial stewardship
- ✓ Promote effective and consistent care among specialists and non-specialists
- ✓ Prompt referral and facilitate communication among the multidisciplinary team

IM pathway specifics

USE OF TOPICAL ANTIMICROBIALS

How does the IM pathway address the key challenge of differential treatment of biofilms and local infections?



*Biofilm suspected when antibiotic / antimicrobial treatments have failed
[†]Spreading / systemic infections are referred to specialists and treated with systemic antibiotics

IM pathway in practice

CLINICAL IMPLICATIONS

The IM pathway is designed to guide specialists and non-specialists in assessment and management of suspected biofilms or local wound infections, and promote consistency of care to help improve patient outcomes and reduce costs if complications are prevented.¹

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

References: 1. Dowsett C, Bellingeri A, Carville K, Garten A, Woo K. A route to more effective infection management: The Infection Management Pathway. *Wounds Int.* 2020;11(3):20–27. 2. Phillips P, Yang Q, Davis S, et al. Antimicrobial dressing efficacy against mature *Pseudomonas aeruginosa* biofilm on porcine skin explants. *Int Wound J.* 2015;12(4):469–483. 3. Roche ED, Woodmansey EJ, Yang Q, Gibson DJ, Zhang H, Schultz GS. Cadexomer iodine effectively reduces bacterial biofilm in porcine wounds ex vivo and in vivo. *Int Wound J.* 2019;16(3):1–10. 4. Fitzgerald DJ, Renick PJ, Forrest E, et al. Cadexomer iodine provides superior efficacy against bacterial wound biofilms in vitro and in vivo. *Wound Repair Regen.* 2017;25:13–24. 5. Gago M, Garcia F, Gaztelu V, Verdu J, Lopez P, Nolasco A. A comparison of three silver-containing dressings in the treatment of infected, chronic wounds. *Wounds.* 2008;20(10):273–278.

Developed by Evidence Communications, Global Clinical & Medical Affairs. Advanced Wound Management, Smith & Nephew, Medical Ltd, 101 Hessle Road, Hull HU3 2BN, UK

AWM-AWC-28179-en V1 1220. Published December 2020. ©2020 Smith+Nephew. ◊Trademark of Smith+Nephew. All Trademarks acknowledged. GMC1255